Clinical trials

January 10, 2018January 10, 2018

Phase 1 Results Support Development of TopiVert Therapy for Ulcerative Colitis

News

Positive safety data from a Phase 1 trial supports TopiVert’s continued development of TOP1288 to treat ulcerative colitis, the British pharma company announced. TOP1288 targets several important enzymes including P38, Src, Lck and ... Read more

July 31, 2017August 18, 2017

Kezar Raises $50M to Support Development of KZR-616 for Autoimmune Diseases

Crohn's Disease, News

Kezar Life Sciences raised $50 million in a financing round to support further clinical development of its lead drug candidate KZR-616 for the treatment of several autoimmune and inflammatory diseases, including ... Read more

May 23, 2017May 23, 2017

Shire’s SHP647 Shows Promise as Potential Ulcerative Colitis Treatment, Study Finds

News

Treatment with SHP647 (also known as PF-00547659) significantly decreased remission rates in a Phase 2 clinical trial of patients with ulcerative colitis, a type of inflammatory bowel disease (IBD). The ... Read more

April 13, 2017

Vitality Biopharma Appoints Regulatory Advisor for Cannabis-Derived Prodrugs Program

News

Vitality Biopharma has appointed Tracy Rockney, co-founder and chief operating officer at OneSource Regulatory, to the position of senior regulatory advisor. She will be responsible for the regulatory development of ... Read more

April 7, 2017

Can Cannabis Help With Your IBD Symptoms?

Many people who suffer from inflammatory bowel disease (IBD) are turning to cannabis (or medical marijuana) to ease some of the symptoms of the disease. In addition to the already converted, there ... Read more

March 14, 2017

New Phase 2 Trials to Evaluate Filgotinib in Two Types of Crohn’s Disease

News

Galapagos NV, collaborating with Gilead Sciences, will soon begin recruiting for announced two new Phase 2 clinical trials to evaluate filgotinib in patients with small bowel Crohn’s disease, as well ... Read more

June 20, 2016June 20, 2016

Shire to License Rights for Pfizer’s IBD Drug PF-00547659

News

The biotechnology company Shire will license global rights from Pfizer for PF-00547659, a drug under development for patients with moderate-to-severe inflammatory bowel disease (IBD). IBD is a group of conditions characterized by inflammation in the ... Read more

May 13, 2016May 13, 2016

Gene Mutations Can Stop Good Gut Bacteria from Easing Crohn’s Disease

Crohn's Disease, IBD News, News

Crohn’s disease patients with certain gene mutations may not benefit from normally helpful bacteria in their guts, new research published in the journal Science revealed. The new insights may alter ... Read more